NDANASALSPRAY, METEREDPriority Review
Approved
Jul 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
RIVIVE (naloxone hydrochloride) by R-Pharm US is clinical pharmacology complete or partial reversal of opioid depression naloxone hydrochloride prevents or reverses the effects of opioids including respiratory depression, sedation, and hypotension. First approved in 2023.
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIVIVE is a nasal spray formulation of naloxone hydrochloride, a pure opioid antagonist approved in July 2023. It rapidly reverses opioid overdose by competing for µ, κ, and σ opioid receptors, with onset of action within two minutes. The drug also reverses respiratory depression, sedation, hypotension, and dysphoric effects of opioid agonist-antagonists.
Growth5.5 years to LOE
Early-stage post-approval product with nasal route positioning for rapid access in overdose emergencies; team expansion likely as market adoption accelerates.
Mechanism of Action
CLINICAL PHARMACOLOGY Complete or Partial Reversal of Opioid Depression Naloxone hydrochloride prevents or reverses the effects of opioids including respiratory depression, sedation, and hypotension. Also, naloxone hydrochloride can reverse the psychotomimetic and dysphoric effects of…
Worked on RIVIVE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.